Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased raf-1 ubiquitin-dependent degradation
暂无分享,去创建一个
M. Marra | A. Abbruzzese | M. Caraglia | A. Giordano | E. Bismuto | A. Budillon | G. Francini | P. Correale | F. Ricciardiello | G. Meo | Giovanni Brachlente
[1] M. Caraglia,et al. Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer , 2005, Cancer Chemotherapy and Pharmacology.
[2] M. Caraglia,et al. Dendritic Cell-Mediated Cross-Presentation of Antigens Derived from Colon Carcinoma Cells Exposed to a Highly Cytotoxic Multidrug Regimen with Gemcitabine, Oxaliplatin, 5-Fluorouracil, and Leucovorin, Elicits a Powerful Human Antigen-Specific CTL Response with Antitumor Activity in Vitro1 , 2005, The Journal of Immunology.
[3] D. Green,et al. Apoptotic Pathways: Ten Minutes to Dead , 2005, Cell.
[4] S. Fulda,et al. Targeting apoptosis pathways in cancer therapy. , 2004, Current cancer drug targets.
[5] A. Abbruzzese,et al. A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma , 2004, British Journal of Cancer.
[6] S. Gibson,et al. Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications. , 2004, Current cancer drug targets.
[7] M. Goetz,et al. The Hsp90 chaperone complex as a novel target for cancer therapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] L. Neckers,et al. Heat shock protein 90 as a molecular target for cancer therapeutics. , 2003, Cancer cell.
[9] W. Pratt,et al. Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery 1 , 2003, Experimental biology and medicine.
[10] Roland Hustinx,et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] Dariusz Leszczynski,et al. Non-thermal activation of the hsp27/p38MAPK stress pathway by mobile phone radiation in human endothelial cells: molecular mechanism for cancer- and blood-brain barrier-related effects. , 2002, Differentiation; research in biological diversity.
[12] G. Milano,et al. Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity , 2002, British Journal of Cancer.
[13] M. Blagosklonny. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs , 2002, Leukemia.
[14] S. Faivre,et al. Etudes précliniques de l'oxaliplatine en polychimiothérapie , 2001 .
[15] J. Buchner,et al. Hsp90: Chaperoning signal transduction , 2001, Journal of cellular physiology.
[16] Jason C. Young,et al. Hsp90: a specialized but essential protein-folding tool. , 2001, The Journal of cell biology.
[17] L. del Peso,et al. Hypoxia Induces the Activation of the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway in PC12 Cells , 2001, The Journal of Biological Chemistry.
[18] D R McKenzie,et al. Mobile phones, heat shock proteins and cancer. , 2001, Differentiation; research in biological diversity.
[19] L. Chaudhary,et al. The cell survival signal Akt is differentially activated by PDGF‐BB, EGF, and FGF‐2 in osteoblastic cells , 2001, Journal of cellular biochemistry.
[20] J. Mendelsohn,et al. Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody , 2001, Oncogene.
[21] S. Kimura,et al. The MEK1‐ERK MAP kinase pathway and the PI 3‐kinase‐Akt pathway independently mediate anti‐apoptotic signals in HepG2 liver cancer cells , 2001, International journal of cancer.
[22] Ulf R. Rapp,et al. Apoptosis Suppression by Raf-1 and MEK1 Requires MEK- and Phosphatidylinositol 3-Kinase-Dependent Signals , 2001, Molecular and Cellular Biology.
[23] Ming-Tsan Lin,et al. The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6 , 2001, Oncogene.
[24] Volker Heinemann,et al. Gemcitabine: Progress in the Treatment of Pancreatic Cancer , 2000, Oncology.
[25] S. Mani,et al. Novel combinations with oxaliplatin. , 2000, Oncology.
[26] G. Hyland. Physics and biology of mobile telephony , 2000, The Lancet.
[27] Honglin Zhou,et al. Akt Regulates Cell Survival and Apoptosis at a Postmitochondrial Level , 2000, The Journal of cell biology.
[28] R. Morimoto,et al. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. , 2000, Journal of the National Cancer Institute.
[29] L. Wiseman,et al. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. , 2000, Drugs.
[30] Alexander Varshavsky,et al. The ubiquitin system. , 1998, Annual review of biochemistry.
[31] T. Cotter,et al. Heat shock proteins – modulators of apoptosis in tumour cells , 2000, Leukemia.
[32] David W. P. Thomas,et al. Cell biology: Non-thermal heat-shock response to microwaves , 2000, Nature.
[33] A. Abbruzzese,et al. Interferon-α induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor , 1999, Cell Death and Differentiation.
[34] L. Garfinkel,et al. U.S. cancer incidence, mortality and survival: 1973-1996. , 1999, Statistical bulletin.
[35] L. Wiseman,et al. Oxaliplatin: a review of its use in the management of metastatic colorectal cancer. , 1999, Drugs & aging.
[36] M. Mayer,et al. Molecular chaperones: The busy life of Hsp90 , 1999, Current Biology.
[37] G L Johnson,et al. Organization and regulation of mitogen-activated protein kinase signaling pathways. , 1999, Current opinion in cell biology.
[38] M. Hidalgo,et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] J. Berlin,et al. A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors , 1998, Investigational New Drugs.
[40] G. Milano,et al. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] D. D. Hoff. Promising new agents for treatment of patients with colorectal cancer. , 1998 .
[42] A. Varshavsky,et al. The ubiquitin system. , 1997, Trends in biochemical sciences.
[43] E. Raymond,et al. [Oxaliplatin: the first DACH platinum in clinical practice]. , 1997, Bulletin du cancer.
[44] C. Tournigand,et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. , 1997, European journal of cancer.
[45] W. Plunkett,et al. Gemcitabine: preclinical pharmacology and mechanisms of action. , 1996, Seminars in oncology.
[46] Marco Lorenzi,et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. , 1994, Gastroenterology.
[47] A. Chen,et al. Antimetabolites , 1992, Cancer chemotherapy and biological response modifiers.
[48] H. Wieand,et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] J. Laurie,et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] J DeMiguel,et al. Cancer of the colon , 1973 .
[51] J. Madden,et al. CANCER OF THE COLON. , 1964, American journal of surgery.
[52] E. Raymond,et al. [Preclinical studies of oxaliplatin in combination chemotherapy]. , 2001, Bulletin du cancer.
[53] F. Lévi,et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] F. Roviello,et al. GEMCITABINE (dFdC), 5-FLUROURACIL (5FU), AND FOLINIC ACID (FA) IN THE TREATMENT OF PATIENTS WITH GASTRO-ENTERIC CARCINOMAS: A CLINICAL AND PHARMACOLOGICAL STUDY. , 2000 .
[55] E. Raymond,et al. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines , 1999, Cancer Chemotherapy and Pharmacology.
[56] A. Abbruzzese,et al. Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. , 1999, Cell death and differentiation.
[57] C. Widmann,et al. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. , 1999, Physiological reviews.
[58] G. Francini,et al. Gemcitabine (dFdC) affects 5-fluorouracil (5-FU9 pharmacokinetic in cancer patients. , 1999 .
[59] M. Kahn,et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] M. Hochstrasser. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. , 1995, Current opinion in cell biology.
[61] J. Misset,et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[62] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.